Myocardial 123I-MIBG scintigraphy imaging for Dementia

Phase-Based Progress Estimates
Mayo Clinic in Rochester, Rochester, MN
Dementia+7 More
meta-iodobenzylguanidine (MIBG) (123I) - Drug
All Sexes
What conditions do you have?

Study Summary

The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.

Eligible Conditions

  • Dementia
  • Parkinsonism
  • Mild Cognitive Impairment (MCI)
  • REM Sleep Behavior Disorder
  • Lewy Body Disease

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 10 years

10 years
Correlate myocardial 123I-MIBG scintigraphy findings

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Myocardial 123I-MIBG scintigraphy imaging
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Myocardial 123I-MIBG scintigraphy imaging · No Placebo Group · Phase 4

Myocardial 123I-MIBG scintigraphy imagingExperimental Group · 2 Interventions: meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy · Intervention Types: Drug, DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 years

Trial Background

Bradley Boeve, Principal Investigator
Principal Investigator
Mayo Clinic
Closest Location: Mayo Clinic in Rochester · Rochester, MN
Photo of Rochester  1Photo of Rochester  2Photo of Rochester  3
2021First Recorded Clinical Trial
7 TrialsResearching Dementia
502 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have one of the syndromes/diagnoses of interest.
You are willing and able to participate in all study-related procedures.
The presence of certain medications that could significantly impact the myocardial 123I-MIBG scintigraphy findings.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.